A structured 2-week follow-up visit in the cascade of care for TB increases case detectionShow others and affiliations
2024 (English)In: The International Journal of Tuberculosis and Lung Disease, ISSN 1027-3719, E-ISSN 1815-7920, Vol. 28, no 3, p. 148-153Article in journal (Refereed) Published
Abstract [en]
OBJECTIVES: Delayed detection in TB due to structural and diagnostic shortcomings is pivotal for disease transmission, morbidity and mortality. We investigated whether an inclusive screening, followed by a structured clinical follow-up (FU) could improve case -finding. METHODS: Patients were recruited from health centres in Bissau, Guinea-Bissau, and Gondar, Ethiopia. A routine FU was done at Week 2. If persisting symptoms were found, patients were investigated using chest X-ray (CXR) and Xpert (R) MTB/RIF, followed by a medical consultation. The main outcome were additional TB patients diagnosed by applying the FU strategy. RESULTS: Of 3,571 adults, 3,285 (95%) were examined at Week 2 FU, where 2,491 (72%) were asymptomatic. Screening patients presenting with cough > 2 weeks alone contributed to the diagnosis of 93 patients (45% of all patients diagnosed here), whereas a TBscore > 3 increased this by 18 (9%); adding a Week 2 FU yielded an additional 94 (46%) patients. Among the 794 (24%) with persisting symptoms, 25 were diagnosed using Xpert and 69 at clinical FU, which constituted 46% (94/205) of the total TB patients diagnosed. CONCLUSION: A Week 2 FU visit, which can be nested into routine healthcare, increased the diagnosis of TB patients by two -fold and avoids diagnostic gaps in the cascade -of -care.
Place, publisher, year, edition, pages
INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) , 2024. Vol. 28, no 3, p. 148-153
Keywords [en]
epidemiology; tuberculosis; case-finding; cascade of care; TBscore
National Category
Respiratory Medicine and Allergy
Identifiers
URN: urn:nbn:se:liu:diva-203796DOI: 10.5588/ijtld.23.0435ISI: 001222158500012PubMedID: 38454179OAI: oai:DiVA.org:liu-203796DiVA, id: diva2:1863587
Note
Funding Agencies|Novo Nordisk Foundation; Scandinavian Society for Anti- microbial Chemotherapy Foundation (Stockholm, Sweden); Swedish Research Council (Stockholm, Sweden); Gondar University (Gondar, Ethiopia)
2024-05-312024-05-312025-02-05